modelL01CX01
Extends from Pharmacokinetic.Models.PK_3C.
Information
| name: | Trabectedin | |
| ATC code: | L01CX01 | route: | intravenous |
| compartments: | 3 | |
| dosage: | 1.5 | mg |
| volume of distribution: | 554 | L |
| clearance: | 36.9 | L/h |
| other parameters in model implementation | ||
Trabectedin is an antineoplastic agent originally derived from the sea squirt Ecteinascidia turbinata and now produced synthetically. It binds to the minor groove of DNA, disrupting the cell cycle and leading to apoptosis. Trabectedin is approved for the treatment of soft tissue sarcomas and relapsed ovarian cancer, often in patients who have failed previous chemotherapy.
Pharmacokinetics
Population pharmacokinetics in adult cancer patients (including both sexes), typically receiving trabectedin via intravenous infusion as a single agent.
References
Poggesi, I, et al., & Perez-Ruixo, JJ (2019). Population pharmacokinetics of trabectedin in adolescent patients with cancer. Cancer chemotherapy and pharmacology 84(4) 707–717. DOI:10.1007/s00280-019-03899-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/31286189
Perez-Ruixo, JJ, et al., & Owen, JS (2007). Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients. Clinical pharmacokinetics 46(10) 867–884. DOI:10.2165/00003088-200746100-00005 PUBMED:https://pubmed.ncbi.nlm.nih.gov/17854236
Zelek, L, et al., & Misset, JL (2006). A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. British journal of cancer 94(11) 1610–1614. DOI:10.1038/sj.bjc.6603142 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16736024
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.Volume | Vdp (from PK_2C) | VdpPerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | VdpPerKg (from PK_2C) | 0.9 | Volume of distribution peripheral(l/kg) |
| Pharmacolibrary.Types.Clearance | k12 (from PK_2C) | 1 | intercompartmental C-P clearance |
| Pharmacolibrary.Types.Clearance | k21 (from PK_2C) | 1 | intercompartmental P-C clearance |
| Pharmacolibrary.Types.Volume | Vdp2 (from PK_3C) | Vdp2PerKg*weight | Volume of distribution (m3) |
| Modelica.Units.SI.SpecificVolume | Vdp2PerKg (from PK_3C) | 0.9 | Volume of distribution peripheral 2 (l/kg) |
| Pharmacolibrary.Types.VolumeFlowRate | k13 (from PK_3C) | 1 | intercompartmental 1-3 clearance (l/min) |
| Pharmacolibrary.Types.VolumeFlowRate | k31 (from PK_3C) | 1 | intercompartmental 3-1 clearance (l/min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | peripheralCPort (from PK_2C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral1 (from PK_2C) | ||
| Interfaces.ConcentrationPort_b | perihperal2Cport (from PK_3C) | ||
| Pharmacolibrary.Types.ConcentrationOutput | C_peripheral2 (from PK_3C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life | |
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral (from PK_2C) | ||
| Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartment | peripheral1 (from PK_3C) | ||
| Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSym | transfer1 (from PK_3C) |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)